Skip to main navigation
follow
#navigation
Skip to main content
follow
#content
Skip to Footer
follow
#footer
Clinical Trials
follow
https://www.biomarin.com/clinical-trials/
Contact Us
follow
https://www.biomarin.com/contact-us/
Careers
follow
https://careers.biomarin.com/
Our Motivation
follow
https://www.biomarin.com/our-motivation/
Patient Stories
follow
https://www.biomarin.com/our-motivation/patient-stories/
Bailey
follow
https://www.biomarin.com/our-motivation/patient-stories/bailey/
Kendra
follow
https://www.biomarin.com/our-motivation/patient-stories/kendra/
Sheri
follow
https://www.biomarin.com/our-motivation/patient-stories/sheri/
Matty
follow
https://www.biomarin.com/our-motivation/patient-stories/matty/
Diseases & Conditions
follow
https://www.biomarin.com/our-motivation/diseases-and-conditions/
PKU
follow
https://www.biomarin.com/our-motivation/diseases-and-conditions/pku/
CLN2 Disease
follow
https://www.biomarin.com/our-motivation/diseases-and-conditions/cln2-disease/
MPS VI
follow
https://www.biomarin.com/our-motivation/diseases-and-conditions/mps-vi/
MPS IVA
follow
https://www.biomarin.com/our-motivation/diseases-and-conditions/mps-iva/
MPS I
follow
https://www.biomarin.com/our-motivation/diseases-and-conditions/mps-i/
Patient & Community Support
follow
https://www.biomarin.com/our-motivation/patient-and-community-support/
Trees of Life
follow
https://www.biomarin.com/our-motivation/patient-and-community-support/trees-of-life/
RARE Scholars
follow
https://www.biomarin.com/our-motivation/patient-and-community-support/rare-scholars/
In the Hemophilia Community
follow
https://www.biomarin.com/our-motivation/patient-and-community-support/in-the-hemophilia-community/
Patient Advocacy
follow
https://www.biomarin.com/our-motivation/patient-and-community-support/patient-advocacy/
BioMarin RareConnections™
follow
https://www.biomarin.com/our-motivation/patient-and-community-support/biomarin-rareconnections/
Grants & Donations
follow
https://www.biomarin.com/our-motivation/patient-and-community-support/grants-donations/
Resource Library
follow
https://www.biomarin.com/our-motivation/resources/
Patient Organizations
follow
https://www.biomarin.com/our-motivation/resources/patient-organizations/
Professional Organizations
follow
https://www.biomarin.com/our-motivation/resources/professional-organizations/
Our Science
follow
https://www.biomarin.com/our-science/
Our Approach
follow
https://www.biomarin.com/our-science/our-approach/
Technical Expertise
follow
https://www.biomarin.com/our-science/our-approach/technical-expertise/
Indication Expansion
follow
https://www.biomarin.com/our-science/our-approach/indication-expansion/
Franchise Building
follow
https://www.biomarin.com/our-science/our-approach/franchise-building/
Our Scientists
follow
https://www.biomarin.com/our-science/our-scientists/
Our Publications
follow
https://www.biomarin.com/our-science/our-publications/
Spotlight
follow
https://www.biomarin.com/our-science/spotlight/
Zeroing in on Therapeutic Drug Targets
follow
https://www.biomarin.com/our-science/spotlight/zeroing-in-on-therapeutic-drug-targets/
Allen Institute Partnership
follow
https://www.biomarin.com/our-science/spotlight/allen-institute-partnership/
Meet Christian Vettermann, Ph.D.
follow
https://www.biomarin.com/our-science/our-scientists/christian-vettermann-ph-d/
Funding & Support
follow
https://www.biomarin.com/our-science/funding-and-support/
Independent Medical Education
follow
https://www.biomarin.com/our-science/funding-and-support/independent-medical-education/
Independent Research
follow
https://www.biomarin.com/our-science/funding-and-support/independent-research/
Grants & Donations
follow
https://www.biomarin.com/our-company/grants-and-donations/
Publication Data Request
follow
https://www.biomarin.com/our-science/funding-and-support/publication-data-request/
Our Treatments
follow
https://www.biomarin.com/our-treatments/
Our Products
follow
https://www.biomarin.com/our-treatments/products/
PALYNZIQ® (pegvaliase-pqpz) Injection for PKU
follow
https://www.biomarin.com/our-treatments/products/palynziq/
Brineura® (cerliponase alfa) for CLN2 Disease
follow
https://www.biomarin.com/our-treatments/products/brineura/
Vimizim® (elosulfase alfa) for Morquio A Syndrome (MPS IVA)
follow
https://www.biomarin.com/our-treatments/products/vimizim/
Kuvan® (sapropterin dihydrochloride) for PKU
follow
https://www.biomarin.com/our-treatments/products/kuvan/
Aldurazyme® (laronidase) for MPS I
follow
https://www.biomarin.com/our-treatments/products/aldurazyme-laronidase-for-mps-i/
Naglazyme® (galsulfase) for MPS VI
follow
https://www.biomarin.com/our-treatments/products/naglazyme-galsulfase-for-mps-vi/
Our Pipeline
follow
https://www.biomarin.com/our-treatments/pipeline/
Valoctocogene Roxaparvovec for Severe Hemophilia A
follow
https://www.biomarin.com/our-treatments/pipeline/valoctocogene-roxaparvovec-for-severe-hemophilia-a/
Vosoritide for Achondroplasia
follow
https://www.biomarin.com/our-treatments/pipeline/vosoritide-for-achondroplasia/
BMN 307 for Phenylketonuria (PKU)
follow
https://www.biomarin.com/our-treatments/pipeline/bmn-307-for-pku/
BMN 331 for Hereditary Angioedema (HAE)
follow
https://www.biomarin.com/our-treatments/pipeline/bmn-331-for-hae/
Compassionate Use Policy
follow
https://www.biomarin.com/our-treatments/compassionate-use-policy/
Our Company
follow
https://www.biomarin.com/our-company/
About Us
follow
https://www.biomarin.com/our-company/about-us/
Our History
follow
https://www.biomarin.com/our-company/about-us/our-history/
Manufacturing Excellence
follow
https://www.biomarin.com/our-company/about-us/manufacturing-excellence/
Message from Chairman and CEO
follow
https://www.biomarin.com/our-company/about-us/message-from-chairman-and-ceo/
Global Compliance & Ethics
follow
https://www.biomarin.com/our-company/about-us/global-compliance-and-ethics/
Corporate Social Responsibility
follow
https://www.biomarin.com/our-company/corporate-social-responsibility/
Diversity, Equity & Inclusion
follow
https://www.biomarin.com/our-company/corporate-social-responsibility/diversity-equity-inclusion/
Environmental Health, Safety and Sustainability (EHS&S)
follow
https://www.biomarin.com/our-company/corporate-social-responsibility/environmental-health-safety-and-sustainability-ehss/
Leadership Team
follow
https://www.biomarin.com/our-company/leadership-team/
Jean-Jacques Bienaimé
follow
https://www.biomarin.com/our-company/leadership-team/jean-jacques-bienaime/
Henry J. Fuchs, M.D.
follow
https://www.biomarin.com/our-company/leadership-team/henry-j-fuchs-m-d/
Jeff Ajer
follow
https://www.biomarin.com/our-company/leadership-team/jeff-ajer/
G. Eric Davis
follow
https://www.biomarin.com/our-company/leadership-team/g-eric-davis/
C. Greg Guyer, Ph.D.
follow
https://www.biomarin.com/our-company/leadership-team/dr-c-greg-guyer-ph-d/
Brian R. Mueller
follow
https://www.biomarin.com/our-company/leadership-team/brian-r-mueller/
Lon Cardon, Ph.D., FMedSci
follow
https://www.biomarin.com/our-company/leadership-team/lon-cardon-ph-d/
Philip Lo Scalzo
follow
https://www.biomarin.com/our-company/leadership-team/philip-lo-scalzo/
Amy Wireman
follow
https://www.biomarin.com/our-company/leadership-team/amy-wireman/
Brinda Balakrishnan, M.D., Ph.D.
follow
https://www.biomarin.com/our-company/leadership-team/dr-brinda-balakrishnan-m-d-ph-d/
Board of Directors
follow
https://www.biomarin.com/our-company/board-of-directors/
Grants & Donations
follow
https://www.biomarin.com/our-company/grants-and-donations/
Investors & Media
follow
https://investors.biomarin.com/
Press Releases
follow
https://investors.biomarin.com/press-releases
Events
follow
https://investors.biomarin.com/events-presentations
Governance
follow
https://investors.biomarin.com/corporate-governance
Management
follow
https://www.biomarin.com/our-company/leadership-team/
Board of Directors
follow
https://www.biomarin.com/our-company/board-of-directors/
Committee Composition
follow
https://investors.biomarin.com/committee-composition
Contact the Board
follow
https://investors.biomarin.com/contact-the-board
SEC Filings
follow
https://investors.biomarin.com/sec-filings
Financials
follow
https://investors.biomarin.com/2021-financials
2021
follow
https://investors.biomarin.com/2021-financials
2020
follow
https://investors.biomarin.com/2020-financials
2019
follow
https://investors.biomarin.com/2019-financials
2018
follow
https://investors.biomarin.com/2018-financials
2017
follow
https://investors.biomarin.com/2017-financials
Annual Reports
follow
https://investors.biomarin.com/annual-reports
Stock Info
follow
https://investors.biomarin.com/stock-information
Historical Data
follow
https://investors.biomarin.com/historical-data
Resources
follow
https://investors.biomarin.com/investor-faqs
FAQs
follow
https://investors.biomarin.com/investor-faqs
Contact Us
follow
https://investors.biomarin.com/contact-us
Email Alerts
follow
https://investors.biomarin.com/email-alerts
Our Motivation
follow
https://www.biomarin.com/our-motivation/
Patient Stories
follow
https://www.biomarin.com/our-motivation/patient-stories/
Diseases & Conditions
follow
https://www.biomarin.com/our-motivation/diseases-and-conditions/
Patient & Community Support
follow
https://www.biomarin.com/our-motivation/patient-and-community-support/
Resource Library
follow
https://www.biomarin.com/our-motivation/resources/
Our Science
follow
https://www.biomarin.com/our-science/
Our Approach
follow
https://www.biomarin.com/our-science/our-approach/
Our Scientists
follow
https://www.biomarin.com/our-science/our-scientists/
Spotlight
follow
https://www.biomarin.com/our-science/spotlight/
Our Publications
follow
https://www.biomarin.com/our-science/our-publications/
Funding & Support
follow
https://www.biomarin.com/our-science/funding-and-support/
Our Treatments
follow
https://www.biomarin.com/our-treatments/
Our Products
follow
https://www.biomarin.com/our-treatments/products/
Our Pipeline
follow
https://www.biomarin.com/our-treatments/pipeline/
Compassionate Use Policy
follow
https://www.biomarin.com/our-treatments/compassionate-use-policy/
Our Company
follow
https://www.biomarin.com/our-company/
About Us
follow
https://www.biomarin.com/our-company/about-us/
Corporate Social Responsibility
follow
https://www.biomarin.com/our-company/corporate-social-responsibility/
Leadership Team
follow
https://www.biomarin.com/our-company/leadership-team/
Board of Directors
follow
https://www.biomarin.com/our-company/board-of-directors/
Grants & Donations
follow
https://www.biomarin.com/our-company/grants-and-donations/
Investors & Media
follow
https://investors.biomarin.com/
Press Releases
follow
https://investors.biomarin.com/press-releases
Events
follow
https://investors.biomarin.com/events-presentations
Governance
follow
https://investors.biomarin.com/corporate-governance
SEC Filings
follow
https://investors.biomarin.com/sec-filings
Financials
follow
https://investors.biomarin.com/financial-information
Stock Info
follow
https://investors.biomarin.com/stock-information
Resources
follow
https://investors.biomarin.com/investor-faqs
Privacy Policy
follow
https://www.medinfoprivacy.com/
Terms of Use
follow
https://www.medinfoterms.com/
LinkedIn
follow
https://www.linkedin.com/company/biomarin/
Facebook
follow
https://www.facebook.com/BioMarinOfficial
Site Map
follow
https://www.biomarin.com/site-map/
Instagram
follow
https://www.instagram.com/biomarinofficial/
Supplier Information
follow
https://www.biomarin.com/supplier-information/
YouTube
follow
https://www.youtube.com/channel/UCsJU_aj8_xNFso8ZkfShRJQ/featured
Glossary
follow
https://www.biomarin.com/glossary/
Learn More ⌃
follow
https://investors.biomarin.com/2021-08-27-European-Commission-Approves-BioMarins-VOXZOGO-R-vosoritide-for-the-Treatment-of-Children-with-Achondroplasia-from-Age-2-Until-Growth-Plates-Close
Learn More about careers with BioMarin ⌃
follow
https://careers.biomarin.com/
Learn More about Sheri ⌃
follow
/our-motivation/patient-stories/sheri/
Learn More about our patient support ⌃
follow
/our-motivation/patient-and-community-support/
View Now ⌃
follow
/our-treatments/pipeline/
View All News and press releases⌃
follow
https://investors.biomarin.com/press-releases
BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates
follow
https://investors.biomarin.com/2021-10-27-BioMarin-Announces-Third-Quarter-2021-Financial-Results-and-Corporate-Updates
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
follow
https://investors.biomarin.com/2021-10-25-BioMarin-to-Participate-in-Four-Upcoming-Virtual-Investor-Conferences
BioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4:30pm ET
follow
https://investors.biomarin.com/2021-10-12-BioMarin-to-Host-Third-Quarter-2021-Financial-Results-Conference-Call-and-Webcast-on-Wednesday,-October-27-at-4-30pm-ET
BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations
follow
https://investors.biomarin.com/2021-10-04-BioMarin-Hires-Industry-Veterans-to-Fill-Key-Roles-in-R-D-and-Technical-Operations
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
follow
https://investors.biomarin.com/2021-09-06-U-S-FDA-Placed-a-Clinical-Hold-on-BMN-307-Phearless-Phase-1-2-Gene-Therapy-Study-in-Adults-with-PKU-Based-on-Interim-Pre-clinical-Study-Findings
European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
follow
https://investors.biomarin.com/2021-08-27-European-Commission-Approves-BioMarins-VOXZOGO-R-vosoritide-for-the-Treatment-of-Children-with-Achondroplasia-from-Age-2-Until-Growth-Plates-Close
BioMarin to Participate in Three Upcoming Virtual Investor Conferences
follow
https://investors.biomarin.com/2021-08-25-BioMarin-to-Participate-in-Three-Upcoming-Virtual-Investor-Conferences
BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates
follow
https://investors.biomarin.com/2021-07-28-BioMarin-Announces-Second-Quarter-2021-Financial-Results-and-Corporate-Updates
Our Motivation
follow
https://www.biomarin.com/our-motivation/
Our Science
follow
https://www.biomarin.com/our-science/
Our Treatments
follow
https://www.biomarin.com/our-treatments/
Our Company
follow
https://www.biomarin.com/our-company/
Investors & Media
follow
https://investors.biomarin.com/
Our History
follow
https://www.biomarin.com/our-company/about-us/our-history/
Our Products
follow
https://www.biomarin.com/our-treatments/products/
Our Pipeline
follow
https://www.biomarin.com/our-treatments/pipeline/
Leadership Team
follow
https://www.biomarin.com/our-company/leadership-team/
Board of Directors
follow
https://www.biomarin.com/our-company/board-of-directors/
Diversity, Equity & Inclusion
follow
https://www.biomarin.com/our-company/corporate-social-responsibility/diversity-equity-inclusion/
Global Contact Information
follow
https://www.biomarin.com/contact-us/
Our Locations
follow
https://www.biomarin.com/contact-us/locations/
Report a Product Complaint
follow
https://www.biomarin.com/contact-us/report-product-complaint/
Report Adverse Event
follow
https://www.biomarin.com/contact-us/report-adverse-event/
Publication Data Request
follow
https://www.biomarin.com/our-science/funding-and-support/publication-data-request/
Funding & Support
follow
https://www.biomarin.com/our-science/funding-and-support/
Careers
follow
https://careers.biomarin.com/
LinkedIn
follow
https://www.linkedin.com/company/biomarin/?viewAsMember=true
Facebook
follow
https://www.facebook.com/BioMarinOfficial
Instagram
follow
https://www.instagram.com/biomarinofficial/
YouTube
follow
https://www.youtube.com/channel/UCsJU_aj8_xNFso8ZkfShRJQ/featured
Privacy Policy
follow
https://www.medinfoprivacy.com/
Terms of Use
follow
https://www.medinfoterms.com/
Site Map
follow
https://www.biomarin.com/site-map/
Supplier Information
follow
https://www.biomarin.com/suppliers/
Slavery Act Statement
follow
/ukmodernslaveryactstatement2020/
Glossary
follow
https://www.biomarin.com/glossary/
Contact Us
follow
https://www.biomarin.com/contact-us/
Privacy Policy
follow
/privacy-policy/
Terms and Conditions
follow
/terms-of-use/
follow
javascript:void(0);